Oncology drug costs—the imaginary crisis?

The Imaginary Trademark Parody Crisis (and the Real One)

In the two decades since the Supreme Court protected a crude rap spoof from copyright liability in Campbell v. Acuff-Rose Music, Inc., courts have grown to understand the great value of parodic expression in trademark cases as well. Today, plausible claims of parody almost always prevail over trademark rights in judicial rulings. This Article demonstrates that it is simply wrong to suggest, as ...

The drug shortage crisis.

Biomarkers in oncology drug development.

Biomarker measurements have become an essential component of oncology drug development, particularly so in this era of targeted therapies. Such measurements ensure that clinical studies are testing our biological hypotheses and can help make the difficult decisions required to choose which drugs to stop developing or de-prioritise. For those drugs taken forward, biomarker measurements may also ...

Oncology Drug Shortages in America

J Adv Pract Oncol 2012;3:96–102 T he issue of drug shortages is only one of the many crucial concerns facing oncology advanced practitioners (APs) in the United States today. However, it may be the most critical issue affecting shortand long-term patient outcomes. Shortterm outcomes may be affected by treatment delays, treatment with less effective alternatives, and increased toxicity. Long-ter...

Ultrasonic drug delivery in Oncology.

Ultrasound-assisted drug delivery is an emerging technique that has the advantage of being non-invasive, efficiently and specifically targeted and controllable. While systemic drugs often show detrimental side effects, their ultrasound-triggered local release at the selected tissue may improve safety and specifity of therapy. An increasing amount of animal and preclinical studies demonstrates h...